Protagen Using UNIarray Platform to ID Biomarkers for Use in Lupus Drug Development
August 05, 2011
Protagen Using UNIarray Platform to ID Biomarkers for Use in Lupus Drug Development
The company has signed an agreement with biopharmaceutical firm SuppreMol to use its UNIarray technology to identify autoantibody signatures of SLE patients enrolled in a phase IIa study of SuppreMol's lead therapeutic SM101.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Protagen to ID Protein Biomarkers in Support of Biogen's MS Drug Development Work
April 1, 2011 / ProteoMonitor - SuppreMol to Use Protagen Biomarker Panel
August 2, 2011 / GenomeWeb Daily News - Protagen Secures Nearly $13M in Funding for Diagnostics Work and Protein Biomarker Validation
September 10, 2010 / ProteoMonitor - Protagen Employs UNIarray Platform to Detect Protein Biomarkers Associated with Infectious Disease
July 9, 2010 / ProteoMonitor - Protagen Collaborates with Bayer Schering on Endometriosis Biomarker Discovery
June 11, 2010 / ProteoMonitor